Editorial: Experimental and Innovative Approaches to Multi-target Treatment of Parkinson's and Alzheimer's Diseases - Volume II

Overview

Journal Front Neurosci

Date 2023 Apr 10

PMID 37034172

Authors

Maria A Tikhonova

Hung-Ming Chang

Sandeep Kumar Singh

Affiliations

Soon will be listed here.

Citing Articles

Network pharmacology‒based analysis of marine cyanobacteria derived bioactive compounds for application to Alzheimer's disease.

Xie R, Chen F, Ma Y, Hu W, Zheng Q, Cao J Front Pharmacol. 2023; 14:1249632.

PMID: 37927608 PMC: 10620974. DOI: 10.3389/fphar.2023.1249632.

GM1 Ganglioside as a Disease-Modifying Therapeutic for Parkinson's Disease: A Multi-Functional Glycosphingolipid That Targets Multiple Parkinson's Disease-Relevant Pathogenic Mechanisms.

Schneider J Int J Mol Sci. 2023; 24(11).

PMID: 37298133 PMC: 10252733. DOI: 10.3390/ijms24119183.

References

Pupyshev A, Klyushnik T, Akopyan A, Singh S, Tikhonova M . Disaccharide trehalose in experimental therapies for neurodegenerative disorders: Molecular targets and translational potential. Pharmacol Res. 2022; 183:106373. DOI: 10.1016/j.phrs.2022.106373. View

Zhang N, Fu J, Gao X, Lu F, Lu Y, Liu S . Integrated Brain Metabolomics and Network Pharmacology Analysis to Reveal the Improvement Effect of Bai Chan Ting on Parkinson's Disease. Biomed Res Int. 2022; 2022:6113093. PMC: 9747319. DOI: 10.1155/2022/6113093. View

Hafez D, Dubiel M, La Spada G, Catto M, Reiner-Link D, Syu Y . Novel benzothiazole derivatives as multitargeted-directed ligands for the treatment of Alzheimer's disease. J Enzyme Inhib Med Chem. 2023; 38(1):2175821. PMC: 9937012. DOI: 10.1080/14756366.2023.2175821. View

Carradori S, Fantacuzzi M, Ammazzalorso A, Angeli A, De Filippis B, Galati S . Resveratrol Analogues as Dual Inhibitors of Monoamine Oxidase B and Carbonic Anhydrase VII: A New Multi-Target Combination for Neurodegenerative Diseases?. Molecules. 2022; 27(22). PMC: 9694798. DOI: 10.3390/molecules27227816. View

Jana S, Nasreen T, Singh S . Discovery of reversible selective monoamine oxidase B inhibitors with anti-acetylcholinesterase activity derived from 4-oxo-N-4-diphenyl butanamides. Future Med Chem. 2023; 15(2):189-210. DOI: 10.4155/fmc-2022-0169. View

Anastassova N, Aluani D, Hristova-Avakumova N, Tzankova V, Kondeva-Burdina M, Rangelov M . Study on the Neuroprotective, Radical-Scavenging and MAO-B Inhibiting Properties of New Benzimidazole Arylhydrazones as Potential Multi-Target Drugs for the Treatment of Parkinson's Disease. Antioxidants (Basel). 2022; 11(5). PMC: 9138090. DOI: 10.3390/antiox11050884. View

Elsbaey M, Igarashi Y, Ibrahim M, Elattar E . Click-designed vanilloid-triazole conjugates as dual inhibitors of AChE and Aβ aggregation. RSC Adv. 2023; 13(5):2871-2883. PMC: 9850456. DOI: 10.1039/d2ra07539c. View

Wu X, Zheng X, Tang H, Zhao L, He C, Zou Y . A network pharmacology approach to identify the mechanisms and molecular targets of curcumin against Alzheimer disease. Medicine (Baltimore). 2022; 101(34):e30194. PMC: 9410577. DOI: 10.1097/MD.0000000000030194. View

Liu C, Sang Z, Pan H, Wu Q, Qiu Y, Shi J . A Novel Multifunctional 5,6-Dimethoxy-Indanone-Chalcone-Carbamate Hybrids Alleviates Cognitive Decline in Alzheimer's Disease by Dual Inhibition of Acetylcholinesterase and Inflammation. Front Aging Neurosci. 2022; 14:922650. PMC: 9289467. DOI: 10.3389/fnagi.2022.922650. View

10.

Qin P, Ran Y, Xie F, Liu Y, Wei C, Luan X . Design, synthesis, and biological evaluation of novel N-Benzyl piperidine derivatives as potent HDAC/AChE inhibitors for Alzheimer's disease. Bioorg Med Chem. 2023; 80:117178. DOI: 10.1016/j.bmc.2023.117178. View

11.

Krolicka E, Kiec-Kononowicz K, Lazewska D . Chalcones as Potential Ligands for the Treatment of Parkinson's Disease. Pharmaceuticals (Basel). 2022; 15(7). PMC: 9317344. DOI: 10.3390/ph15070847. View

12.

Wang S, Ma Y, Huang Y, Hu Y, Huang Y, Wu Y . Potential bioactive compounds and mechanisms of for the treatment of Alzheimer's disease analyzed by network pharmacology and molecular docking prediction. Front Aging Neurosci. 2022; 14:1052249. PMC: 9772884. DOI: 10.3389/fnagi.2022.1052249. View